Skip to content

European Myeloma Network (EMN) Sample Project

EMN Prospective Sample Collection Project

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06237803
Acronym
EMN36
Enrollment
6000
Registered
2024-02-01
Start date
2022-12-21
Completion date
2037-12-31
Last updated
2025-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extramedullary Myeloma, MGUS, Multiple Myeloma, Plasma Cell Leukemia, Smoldering Multiple Myeloma

Brief summary

This is an observational, non-interventional, multicenter study for the prospective collection, storage and analysis of patients' biological samples. This study establishes a common international infrastructure useful to collect standard clinical variables at baseline and during treatment and to uniformly collect and store biological samples

Interventions

OTHERstorage of biological samples

collect and store biological samples

Sponsors

Janssen, LP
CollaboratorINDUSTRY
European Myeloma Network B.V.
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Subjects with MGUS, smouldering Multiple Myeloma (SMM) , MM (Multiple Myeloma) (+/- EMD), plasma cell leukemia (PCL) (+/- EMD) * Subjects are ≥ 18 years old. * Subjects have provided written informed consent in accordance with federal, local, and institutional guidelines prior to initiation of any project-specific activities or procedures. 1. Subjects do not have kind of condition that, in the opinion of the Investigators, may compromise the ability of the subjects to give written informed consent and 2. subjects are, in the investigator's opinion, willing and able to comply with the protocol requirements.

Exclusion criteria

* Previous treatment with anti-myeloma therapy (excluding one course of therapy in patients in which urgent therapy is deemed necessary according to physician's discretion, e.g. myeloma-related complications resistant to supportive care). * Subjects have had prior unforeseen (serious) adverse reactions to blood donation including, but not limited to fainting, angina, severe bruising, allergic reactions, or any other adverse events. * Any psychological, familial, sociological and geographical condition potentially hampering compliance with the protocol and follow-up schedule.

Design outcomes

Primary

MeasureTime frameDescription
Biobankup to 30 yearsCollect biological samples for research studies related to improving medicine and care to the patient

Countries

Australia, Austria, Belgium, Czechia, Greece, Ireland, Italy, Portugal, Serbia, Switzerland

Contacts

Primary ContactChiara Del Pietro
chiara.delpietro@emn.org+31 10702687065

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026